Boesecke, Christoph http://orcid.org/0000-0003-0686-6537
Schellberg, Sven http://orcid.org/0009-0008-1117-7836
Schneider, Jochen http://orcid.org/0000-0002-0300-0159
Schuettfort, Gundolf http://orcid.org/0000-0001-6828-4116
Stocker, Hartmut http://orcid.org/0000-0001-9656-8474
Article History
Received: 4 April 2023
Accepted: 10 June 2023
First Online: 20 July 2023
Declarations
:
: CB has received fees from Gilead Sciences, Hexal AG, MSD and Janssen-Cilag for lectures and/or advice, and travel grants for scientific conferences from Gilead Sciences, MSD and Janssen-Cilag. SS has received grants and funding for clinical studies, advisory boards and lectures from Gilead Sciences, ViiV Healthcare, Thera Therapeuticals, MSD, Janssen, Hormosan and the German Innovationsfonds. JS has received grants and/or personal fees from Gilead Sciences, Dr Falk Pharma, GmbH, MSD, Janssen-Cilag and AbbVie. GS has received funding from Gilead Sciences and fees from ViiV Healthcare, Bristol Myers Squibb, MSD and Hormosan for participation in advisory boards, data safety and monitoring boards, and for the preparation of educational materials and lectures. HS has received grants and honoraria for presentations and advisory boards from Gilead Sciences, MSD, ViiV Healthcare and Janssen. Medical writing support was provided by Michael Molloy-Bland PhD and Emily Manktelow PhD, of Oxford PharmaGenesis, Melbourne, Australia, and funded by Gilead Sciences Europe Ltd.
: This is a review article and ethical approval is not applicable.